Annovis Bio Inc

Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission

Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study

Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results